Slide
Slide

Central Nervous System Portfolio

Preclinical

Phase I

Phase II

Phase III

TNX-102 SL   Fibromyalgia (FM)
Two positive Phase 3 studies completed, expect to file NDA in 2nd Half 2024

Mid-Phase III

TNX-102 SL   Long COVID
Phase II start — PREVAIL study enrollment complete

Phase II

TNX-1300   Cocaine Intoxication / Overdose
Mid-Phase II — Breakthrough Therapy Designation

Mid-Phase II

Immunology Portfolio

Preclinical

Phase I

Phase II

Phase III

TNX-1500   Organ Transplant Rejection / Autoimmune Disorders
Phase I start — currently enrolling

Preclinical

TNX-1700  Gastric and Colorectal Cancer
Preclinical

Preclinical

Infectious Disease Portfolio

Preclinical

Phase I

Phase II

Phase III

TNX-801  Smallpox and Monkeypox Preventing Vaccine
Preclinical

Preclinical

TNX-1800   COVID-19 Vaccine
Preclinical

Preclinical

Rare Disease Portfolio

Preclinical

Phase I

Phase II

Phase III

TNX-2900   Prader-Willi Syndrome
Phase II ready – FDA Orphan Drug Designation

Preclinical